Should Tuberculin Skin Test Be Positive to Give Latent Tuberculosis Treatment Before Tumor Necrosis Factor-α α Inhibitors in Selected Patients in Developing Countries?

To the Editor:
We read with interest the report by Malaviya, et al about tuberculosis (TB) and inflammatory rheumatic disease (IRD) patients receiving tumor necrosis factor-α (TNF-α) inhibitor agents 1 . Mexico also has a "high TB burden," with estimated prevalence of at least 23 per 100,000 2 . The tuberculin skin test (TST) has low sensitivity, including in high-risk population groups such as men and patients older than 50 years, in addition to those who have disseminated TB 3, 4 . In immunosuppressed patients (such as those with human immunodeficiency virus), tuberculin anergy is reported to be > 40%, particularly in those with poor body mass index and/or severe lymphopenia 5 . This could also be true about other immunodeficient persons, including patients with rheumatic disease who are taking disease-modifying antirheumatic drugs (DMARD) and corticosteroids 6, 7 .
One of 22 patients reported by Malaviya, et al who tested negative for TB (TST, Quanti-FERON-TB Gold, standard chest radiograph, and computed tomography scan) developed TB 8 weeks after 1 dose of TNF-α inhibitor agents 1 . We have 5 patients with IRD with TST-negative active TB; 1 of them had systemic lupus erythematosus (SLE) treated with infliximab because of refractory polyarthritis. That patient had acute respiratory failure secondary to disseminated fulminating TB, identified in necropsy 2 weeks after death to have received the first administration of infliximab (previous normal chest radiograph). Only 1 of these patients with IRD was not treated with DMARD and received prednisone > 10 mg (Table 1) .
To see whether there were differences among our cases and patients without IRD, we evaluated 54 patients without IRD and with active TB (excluding other immune-suppression causes). The average age was 39.4 years; 51.9% were female and 29.6% TST-negative; most of them had pulmonary TB (61%). We did not find TST differences between patients with pulmonary disease (70%, 23/33) and those with extrapulmonary disease (71.4%, 15/21; p > 0.05). Moreover, our healthy population has a high frequency of positive TST (> 10 mm). We found this in 65% of 650 first-year medical students (mean age 18 yrs), who had not started clinical practice and did not have any potential contact with TB patients. But we cannot explain why < 20% of our IRD patients have positive TST.
It is evident that our patients have a high risk of developing active TB independent of TST results. It is interesting that the treatment with TNF-α inhibitor agents does not decrease the sensitivity of TST. In addition, we have found that 10% of patients under biologic therapy (non-TNF-α inhibitor agents) who previously were TST-negative can change to positive. It has also been found that patients taking TNF-α inhibitor agents maintained or increased their TST positivity 8 . Developed countries have reported patients with previous negative TST being diagnosed with TB after taking TNF-α inhibitor agents and normal chest radiograph 9 . These considerations are important because we recognize that the TST has low sensitivity for diagnosis of latent TB. Malaviya, et al reported in India an incidence of 18.2% of TB disease flare in patients treated with TNF-α inhibitor agents with a "standard" screening strategy for latent TB, and 4.5% with the "modified" TB screening strategy 1 .
For developing countries where latent TB has a high prevalence, and despite negative screening tests for TB, we propose that before starting TNF-α inhibitor treatment, patients should receive prophylactic therapy or treatment for latent TB. TB disease flares could be brought close to zero, or at least near 1% as quoted from randomized controlled trials of TNF-α inhibitor agents 10 .
In Mexico, as in other developing countries having high TB prevalence, it could be reasonable to receive therapy for latent TB before taking TNF-α inhibitor agents, independent of the TST results. We do not know the maintenance time for TB therapy, because we do not have evidence that after the recommended 9 months of therapy, the TB risk could be modified. These considerations are expressed because although we had only 5 patients with IRD who developed active TB, one of them under TNF-α inhibitor therapy, the diagnosis of active TB was made in most of our patients with invasive methods. 
